Endocrinology and Metabolism

Cecilia A. Jimeno (Jimeno CA)

2 Articles

Clinical Study
Factors Associated with Postoperative Diabetes Insipidus after Pituitary Surgery: Antonio L. Faltado, Anna Angelica Macalalad-Josue, Ralph Jason S. Li, John Paul M. Quisumbing, Marc Gregory Y. Yu, Cecilia A. Jimeno; Endocrinol Metab. 2017;32(4):426-433. Published online November 21, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.4.426

4,196 View
80 Download
8 Citations

Abstract PDF PubReader Crossref - TDM

Background

Determining risk factors for diabetes insipidus (DI) after pituitary surgery is important in improving patient care. Our objective is to determine the factors associated with DI after pituitary surgery.

Methods

We reviewed records of patients who underwent pituitary surgery from 2011 to 2015 at Philippine General Hospital. Patients with preoperative DI were excluded. Multiple logistic regression analysis was performed and a predictive model was generated. The discrimination abilities of the predictive model and individual variables were assessed using the receiving operator characteristic curve.

Results

A total of 230 patients were included. The rate of postoperative DI was 27.8%. Percent change in serum Na (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.15 to 1.69); preoperative serum Na (OR, 1.19; 95% CI, 1.02 to 1.40); and performance of craniotomy (OR, 5.48; 95% CI, 1.60 to 18.80) remained significantly associated with an increased incidence of postoperative DI, while percent change in urine specific gravity (USG) (OR, 0.53; 95% CI, 0.33 to 0.87) and meningioma on histopathology (OR, 0.05; 95% CI, 0.04 to 0.70) were significantly associated with a decreased incidence. The predictive model generated has good diagnostic accuracy in predicting postoperative DI with an area under curve of 0.83.

Conclusion

Greater percent change in serum Na, preoperative serum Na, and performance of craniotomy significantly increased the likelihood of postoperative DI while percent change in USG and meningioma on histopathology were significantly associated with a decreased incidence. The predictive model can be used to generate a scoring system in estimating the risk of postoperative DI.

Citations

Citations to this article as recorded by

Correlation of Pituitary Descent and Diabetes Insipidus After Transsphenoidal Pituitary Macroadenoma Resection
Josh Ma, Peter Gooderham, Ryojo Akagami, Serge Makarenko
Neurosurgery.2023;[Epub] CrossRef
Change in cephalocaudal tumor cavity diameter after transsphenoidal surgery is a predictor of diabetes insipidus in pituitary adenoma
Kunzhe Lin, Kaichun Fan, Shuwen Mu, Shousen Wang
European Journal of Medical Research.2022;[Epub] CrossRef
Change in the pituitary stalk deviation angle after transsphenoidal surgery can predict the development of diabetes insipidus for pituitary adenomas
Liang Xue, Jianwu Wu, Jie Chen, Yongkai Yang
Endocrine Connections.2022;[Epub] CrossRef
Disorders of Salt and Water Balance After Pituitary Surgery
Emily K Brooks, Warrick J Inder
The Journal of Clinical Endocrinology & Metabolism.2022; 108(1): 198. CrossRef
Postoperative diabetes insipidus: how to define and grade this complication?
Friso de Vries, Daniel J. Lobatto, Marco J. T. Verstegen, Wouter R. van Furth, Alberto M. Pereira, Nienke R. Biermasz
Pituitary.2021; 24(2): 284. CrossRef
Diaphragma sellae sinking can predict the onset of hyponatremia after transsphenoidal surgery for pituitary adenomas
Kunzhe Lin, Jun Li, Lingling Lu, Shangming Zhang, Shuwen Mu, Zhijie Pei, Cheng Wang, Jingying Lin, Liang Xue, Liangfeng Wei, Lin Zhao, Shousen Wang
Journal of Endocrinological Investigation.2021; 44(11): 2511. CrossRef
Adrenocorticotropic hormone-secreting pituitary macroadenoma: A pictorial case report and review
Ujjwala Murkute
Indian Journal of Continuing Nursing Education.2021; 22(2): 137. CrossRef
Sodium Perturbations After Pituitary Surgery
Kevin C.J. Yuen, Adnan Ajmal, Ricardo Correa, Andrew S. Little
Neurosurgery Clinics of North America.2019; 30(4): 515. CrossRef

Clinical Study
Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults: Abigail U. Canto, Paulette N. Dominguez, Cecilia A. Jimeno, Jerry M. Obaldo, Ruben V. Ogbac; Endocrinol Metab. 2016;31(1):168-173. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.168

3,502 View
40 Download
9 Citations

Abstract PDF PubReader Crossref - TDM

Background

Radioactive iodine as a treatment modality has been shown in several studies to be a safe and effective therapy for Graves disease. However, there is still no uniformity regarding optimal dosing method. The aim of this study is to compare the efficacy of calculated and fixed dosing of radioiodine for the treatment of Graves disease.

Methods

A hundred twenty-two patients diagnosed with Graves disease were randomized to receive either fixed or calculated dose of radioiodine. Those randomized to fixed activity received either low fixed activity at 9.9 mCi for thyroid gland size <40 g or high fixed activity at 14.9 mCi for thyroid gland size 40 to 80 g, and those grouped to calculated activity received 160 µCi/g of thyroid tissue adjusted for 24 hours radioiodine uptake. Thyroid function tests (free thyroxine [T4] and thyroid stimulating hormone [TSH]) were monitored at 10, 16, and 24 weeks after radioactive iodine therapy. The primary outcome, treatment failure was defined as persistently elevated free T4 and low TSH.

Results

Of the 122 patients randomized, 56 in the fixed dose group and 56 in the calculated dose group completed the follow-up. At the end of 6 months, the percentage of treatment failure was 37.50% in the calculated dose group versus 19.64% in the fixed dose group with a relative risk of 0.53 (95% confidence interval, 0.28 to 0.98) favoring the fixed dose group.

Conclusion

Fixed dose radioiodine has a significantly lower incidence of persistent hyperthyroidism at 6 months post-radioactive therapy.

Citations

Citations to this article as recorded by

Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience
Busra Kuyumcu Demir, Ersen Karakilic, Emre Sedar Saygili, Nilgun Araci, Semra Ozdemir
Endocrine Practice.2022; 28(8): 749. CrossRef
Changes in Radiosensitivity to Gamma-Rays of Lymphocytes from Hyperthyroid Patients Treated with I-131
Valentina Dini, Massimo Salvatori, Mauro Belli, Maria Elena Lago, Alessandra Nosdeo, Donatella Pia Dambra, Luisa Lo Conte, Ilaria Pecchia, Alessandro Giordano
International Journal of Molecular Sciences.2022; 23(17): 10156. CrossRef
Current controversies in the management of Graves’ hyperthyroidism
Niroshan Francis, Thanuya Francis, John H Lazarus, Onyebuchi E Okosieme
Expert Review of Endocrinology & Metabolism.2020; 15(3): 159. CrossRef
Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves’ Ophthalmopathy
Shahrara Ariamanesh, Narjess Ayati, Zahra Mazloum Khorasani, Zohreh Mousavi, Victoria Kiavash, Zahra Kiamanesh, Seyed Rasoul Zakavi
Clinical Nuclear Medicine.2020; 45(7): 514. CrossRef
The relationship between thyroid eye disease and radioiodine treatment
Sarameth Thou, Sobhan Vinjamuri
Nuclear Medicine Communications.2019; 40(3): 194. CrossRef
99mTc-pertechnetate thyroid scintigraphy predicts clinical outcomes in personalized radioiodine treatment for Graves’ disease
Zhao Lina, Zhang Wenqi, Xin Yubo, Wen Qiang, Bail Lin, Guan Feng, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2018; 37(6): 349. CrossRef
Predicción de los resultados clínicos en el tratamiento personalizado con yodo radiactivo de la enfermedad de Graves, mediante gammagrafía tiroidea con 99mTc-pertecnetato
L. Zhao, W. Zhang, Y. Xin, Q. Wen, L. Bail, F. Guan, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular.2018; 37(6): 349. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders
Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
Nuclear Medicine Communications.2017; 38(9): 756. CrossRef

Author index